Efficacy and Safety of Low-molecular-weight Heparin in Patients with Sepsis: a Meta-analysis of Randomized Controlled Trials

Overview

Journal Sci Rep

Specialty Science

Date 2016 May 17

PMID 27181297

Citations 34

Authors

Yu Fan

Menglin Jiang

Dandan Gong

Chen Zou

Affiliations

Soon will be listed here.

Abstract

Low-molecular-weight heparin (LMWH) is part of standard supportive care. We conducted a meta-analysis to investigate the efficacy and safety of LMWH in septic patients. We searched Pubmed, Embase, CKNI and Wanfang database prior to July 2015 for randomized controlled trials investigating treatment with LMWH in septic patients. We identified 11 trials involving 594 septic patients. Meta-analysis showed that LMWH significantly reduced prothrombin time (mean differences [MD] -0.88; 95% CI -1.47 to -0.29), APACHE II score (MD -2.50; 95% CI -3.55 to -1.46), and 28-day mortality (risk ratio [RR] 0.72; 95% CI 0.57-0.91) as well as increased the platelet counts (MD 18.33; 95% CI 0.73-35.93) than the usual treatment. However, LMWH did not reduce D-dimer (MD -0.34; 95% CI -0.85 to 0.18). LMWH also significantly increased the bleeding events (RR 3.82; 95% CI 1.81-8.08). LMWH appears to reduce 28-day mortality and APACHE II score among septic patients. Bleeding complications should be monitored during the LMWH treatment. As for limited data about LMWH and sepsis in the English literature, only trials published in the Chinese were included in the meta-analysis.

Citing Articles

Disseminated intravascular coagulation: cause, molecular mechanism, diagnosis, and therapy.

Gong F, Zheng X, Zhao S, Liu H, Chen E, Xie R MedComm (2020). 2025; 6(2):e70058.

PMID: 39822757 PMC: 11733103. DOI: 10.1002/mco2.70058.

Heparin therapy in sepsis and sepsis-associated disseminated intravascular coagulation: a systematic review and meta-analysis.

Totoki T, Koami H, Makino Y, Wada T, Ito T, Yamakawa K Thromb J. 2024; 22(1):84.

PMID: 39350146 PMC: 11440886. DOI: 10.1186/s12959-024-00653-0.

Bacterial Porins and Their Procoagulant Role: Implication in the Pathophysiology of Several Thrombotic Complications during Sepsis.

Siniscalchi C, Perrella A, Trama U, Bernardi F, Imbalzano E, Camporese G Toxins (Basel). 2024; 16(8).

PMID: 39195778 PMC: 11359280. DOI: 10.3390/toxins16080368.

Heparanase inhibitor improves clinical study in patients with septic cardiomyopathy.

Chen D, Li H, Huang S, Huang Z, Sun Y, Liu L Front Med (Lausanne). 2024; 11:1429109.

PMID: 39170046 PMC: 11335619. DOI: 10.3389/fmed.2024.1429109.

HMG-CoA reductase inhibitors and the attenuation of risk for disseminated intravascular coagulation in patients with sepsis.

Alana N, Ciurylo W, Hurlock N J Thromb Thrombolysis. 2023; 57(2):260-268.

PMID: 37945940 DOI: 10.1007/s11239-023-02910-x.

References

Cornet A, Smit E, Beishuizen A, Groeneveld A . The role of heparin and allied compounds in the treatment of sepsis. Thromb Haemost. 2007; 98(3):579-86. View

Levi M, Schultz M, van der Poll T . Sepsis and thrombosis. Semin Thromb Hemost. 2013; 39(5):559-66. DOI: 10.1055/s-0033-1343894. View

OBrien M . The reciprocal relationship between inflammation and coagulation. Top Companion Anim Med. 2012; 27(2):46-52. DOI: 10.1053/j.tcam.2012.06.003. View

Danai P, Martin G . Epidemiology of sepsis: recent advances. Curr Infect Dis Rep. 2005; 7(5):329-34. DOI: 10.1007/s11908-005-0005-1. View

Cheng B, Xie G, Yao S, Wu X, Guo Q, Gu M . Epidemiology of severe sepsis in critically ill surgical patients in ten university hospitals in China. Crit Care Med. 2007; 35(11):2538-46. DOI: 10.1097/01.CCM.0000284492.30800.00. View

Cinel I, Opal S . Molecular biology of inflammation and sepsis: a primer. Crit Care Med. 2008; 37(1):291-304. DOI: 10.1097/CCM.0b013e31819267fb. View

Ai Y, Zhang L, Gong H, Xu D, Zhao S, Chen J . [Clinical study of low molecular weight heparin therapy for sepsis]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2006; 17(12):736-9. View

Rodelo J, De La Rosa G, Valencia M, Ospina S, Arango C, I Gomez C . D-dimer is a significant prognostic factor in patients with suspected infection and sepsis. Am J Emerg Med. 2012; 30(9):1991-9. DOI: 10.1016/j.ajem.2012.04.033. View

Nandurkar H, Chong B, Salem H, Gallus A, Ferro V, McKinnon R . Low-molecular-weight heparin biosimilars: potential implications for clinical practice. Australian Low-Molecular-Weight Heparin Biosimilar Working Group (ALBW). Intern Med J. 2014; 44(5):497-500. DOI: 10.1111/imj.12417. View

10.

Semeraro N, Ammollo C, Semeraro F, Colucci M . Sepsis, thrombosis and organ dysfunction. Thromb Res. 2011; 129(3):290-5. DOI: 10.1016/j.thromres.2011.10.013. View

11.

Dellinger R, Levy M, Rhodes A, Annane D, Gerlach H, Opal S . Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013; 39(2):165-228. PMC: 7095153. DOI: 10.1007/s00134-012-2769-8. View

12.

Gray E . Standardisation of unfractionated and low-molecular-weight heparin. Handb Exp Pharmacol. 2012; (207):65-76. DOI: 10.1007/978-3-642-23056-1_4. View

13.

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View

14.

Knoebl P . Blood coagulation disorders in septic patients. Wien Med Wochenschr. 2010; 160(5-6):129-38. DOI: 10.1007/s10354-009-0738-9. View

15.

Zarychanski R, Abou-Setta A, Kanji S, Turgeon A, Kumar A, Houston D . The efficacy and safety of heparin in patients with sepsis: a systematic review and metaanalysis. Crit Care Med. 2014; 43(3):511-8. DOI: 10.1097/CCM.0000000000000763. View

16.

Okamoto K, Tamura T, Sawatsubashi Y . Sepsis and disseminated intravascular coagulation. J Intensive Care. 2016; 4:23. PMC: 4804491. DOI: 10.1186/s40560-016-0149-0. View

17.

Hack C, Aarden L, Thijs L . Role of cytokines in sepsis. Adv Immunol. 1997; 66:101-95. DOI: 10.1016/s0065-2776(08)60597-0. View

18.

Oda S, Aibiki M, Ikeda T, Imaizumi H, Endo S, Ochiai R . The Japanese guidelines for the management of sepsis. J Intensive Care. 2015; 2(1):55. PMC: 4336273. DOI: 10.1186/s40560-014-0055-2. View

19.

Levi M, van der Poll T . Inflammation and coagulation. Crit Care Med. 2010; 38(2 Suppl):S26-34. DOI: 10.1097/CCM.0b013e3181c98d21. View

20.

Barie P, Hydo L, Shou J, Eachempati S . Efficacy of therapy with recombinant human activated protein C of critically ill surgical patients with infection complicated by septic shock and multiple organ dysfunction syndrome. Surg Infect (Larchmt). 2011; 12(6):443-9. DOI: 10.1089/sur.2011.133. View